Search

Thyroid cancer (TC) is a malignancy that is increasing in prevalence on a global scale, necessitating the development of innovative approaches for both diagnosis and treatment. Myo-inositol (MI) plays a crucial role in a wide range of physiological and pathological functions within human cells. To date, studies have investigated the function of MI in thyroid physiology as well as its potential therapeutic benefits for hypothyroidism and autoimmune thyroiditis. However, research in the field of TC is very restricted. Metabolomics studies have highlighted the promising diagnostic capabilities of MI, recognizing it as a metabolic biomarker for identifying thyroid tumors. Furthermore, MI can influence therapeutic characteristics by modulating key cellular pathways involved in TC. This review evaluates the potential application of MI as a naturally occurring compound in the management of thyroid diseases, including hypothyroidism, autoimmune thyroiditis, and especially TC. The limited number of studies conducted in the field of TC emphasizes the critical need for future research to comprehend the multifaceted role of MI in TC. A significant amount of research and clinical trials is necessary to understand the role of MI in the pathology of TC, its diagnostic and therapeutic potential, and to pave the way for personalized medicine strategies in managing this intricate disease. [ABSTRACT FROM AUTHOR]

Our hypothesis is that myoinositol and metformin in pregnant women with high-risk factors for glucose intolerance would reduce insulin resistance and consequently lower the incidence of gestational diabetes mellitus (GDM), a metabolic disorder of pregnancy characterized by maternal hyperglycemia due to deficient response to physiological insulin resistance, which may have a negative impact on perinatal outcome and long-term sequelae. In recent years, this pathology has become increasingly important given the global obesity epidemic and the delay in becoming pregnant, especially in industrialized countries. For this reason, the attempt to prevent, rather than cure, gestational diabetes is particularly important. In addition to lifestyle changes (especially diet and doing more exercise), myoinositol and metformin are the most promising factors at the moment, although not all RCTs published so far agree on their real effectiveness. A review of the articles published so far allows us to assume, albeit with some distinctions, that they can play a positive role. [ABSTRACT FROM AUTHOR]

The article presents an analysis of publications on myoinositol in order to clarify the possibilities of prescribing drugs based on it. Myoinositol is one of the endogenous human metabolites that has a significant effect on the functioning of cells and tissues of the whole body. The main function of myoinositol and its derivatives is to participate in intracellular signal transmission and ensure the functioning of such important receptors as insulin receptors, catecholamines, metabotropic receptors of various neurotransmitters, growth factors, etc. (Myoinositol is the basis for the synthesis of an important group of signaling molecules, inositol phosphates, which mediate signal transmission from growth factor receptors and neurotransmitters). Most inositol-dependent proteins with known functions are necessary for the vital functions of the cardiovascular, immune system, and connective tissue structure. Equally important is the role of myoinositol in maintaining the functioning of the central nervous system (including neurotrophic and neuroprotective roles), sugar metabolism (primarily the signaling cascade of insulin) and the functioning of the kidneys and liver. Myoinositol subsidies contribute to the prevention of folate-resistant malformations and neuroprotection of the brain under stress.

Introduction & Methods: The aim of the study is to assess the Role of Myoinositol & Metformin on clinical, hormonal & metabolic profile of patients in Poly cystic Ovarian Syndrome. The women started with the intake of Myoinositol at a dosage of 2000 mg and 500 mg metformin used for a period of 01 Year. The primary outcome of the study was to determine the restoration of normal menstrual cycles, improvement in acne, reduction in hirsutism, weight loss & fertility. Results: We found maximum cases in 25-29.9 i.e. 51%. BMI - The chi-square statistic is 0.0003. The p-value is .047363. The result is significant at p < .05. Mean fasting blood glucose - 93.44±8.27. Mean Ultrasound Pelvis - 16.92±4.48 & Mean TSH - 2.73±2.66 Conclusion: In the present study, both Metformin and MI were equally effective in improving the clinical, metabolic, and hormonal profile in PCOS patients. BMI was significantly reduced by both the metformin and MI after 12 weeks of treatment. According to the available evidence on this molecule derived from inositol, MYO should be considered an effective and safe treatment for obese and non-obese women with PCOS with insulin resistance and hyperinsulinemia, administered with the aim of improving oocyte quality and maturation and the reproductive prognosis in patients. Treatment with metformin (MET) ameliorated the insulin sensitivity and decreased the androgens levels, but the limitations to MET use are its gastrointestinal side effects. [ABSTRACT FROM AUTHOR]

Copyright of Turkish Journal of Obstetrics & Gynecology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Thyroid cancer (TC) is a malignancy that is increasing in prevalence on a global scale, necessitating the development of innovative approaches for both diagnosis and treatment. Myo-inositol (MI) plays a crucial role in a wide range of physiological and pathological functions within human cells. To date, studies have investigated the function of MI in thyroid physiology as well as its potential therapeutic benefits for hypothyroidism and autoimmune thyroiditis. However, research in the field of TC is very restricted. Metabolomics studies have highlighted the promising diagnostic capabilities of MI, recognizing it as a metabolic biomarker for identifying thyroid tumors. Furthermore, MI can influence therapeutic characteristics by modulating key cellular pathways involved in TC. This review evaluates the potential application of MI as a naturally occurring compound in the management of thyroid diseases, including hypothyroidism, autoimmune thyroiditis, and especially TC. The limited number of studies conducted in the field of TC emphasizes the critical need for future research to comprehend the multifaceted role of MI in TC. A significant amount of research and clinical trials is necessary to understand the role of MI in the pathology of TC, its diagnostic and therapeutic potential, and to pave the way for personalized medicine strategies in managing this intricate disease.

Introduction: The prevalence of Polycystic Ovarian Syndrome (PCOS), one of the common endocrine disorders among women of reproductive age, varies from 2.2% to 26% globally. The treatment for PCOS aims to reduce Body Mass Index (BMI), improve underlying hormonal disturbances, prevent future reproductive and metabolic complications, and enhance the quality of life. Aim: To evaluate the efficacy of metformin and Myoinositol (MI) on the metabolic, hormonal, and clinical profiles in PCOS. Materials and Methods: An open-label randomised clinical trial was conducted at the Department of Obstetrics and Gynaecology, SRM Medical College Hospital and Research Centre, Kattankulathur, Chengelpet, Tamil Nadu, India, from January 2019 to May 2020. The study included 80 women with PCOS who were randomly assigned to two groups. One group received metformin 1500 mg/day (in three divided doses), while the other group received MI 1 gram/day for three months. At the end of the 12-week therapy, the participants were evaluated for changes in clinical, metabolic, and hormonal profiles. The data were analysed using Statistical Package for Social Sciences (SPSS) version 20.0. Descriptive statistics such as frequency, proportion, mean, and standard deviation were used for quantitative data. Results: Both the metformin and MI-treated groups showed a significant reduction in BMI, fasting blood glucose, and fasting insulin. Both drugs were equally effective in changing the hormonal profile. There was a significant improvement in lipid parameters in both groups, with High-density Lipoprotein (HDL) levels being more significantly raised in the metformin group. The post-treatment HDL values in the metformin group were 75.69±19.16 mg/dL compared to 41.43±6.18 mg/dL in the MI group (p

Postharvest deterioration is among the major challenges for the fruit industry. Regulation of the fruit softening rate is an effective strategy for extending shelf-life and reducing the economic losses due postharvest deterioration. The tomato myoinositol monophosphatase 3 gene SlIMP3, which showed highest expression level in fruit, was expressed and purified. SlIMP3 demonstrated high affinity with the L-Gal 1-P and D-Ins 3-P, and acted as a bifunctional enzyme in the biosynthesis of AsA and myoinositol. Overexpression of SlIMP3 not only improved AsA and myoinositol content, but also increased cell wall thickness, improved fruit firmness, delayed fruit softening, decreased water loss, and extended shelf-life. Overexpression of SlIMP3 also increased uronic acid, rhamnose, xylose, mannose, and galactose content in cell wall of fruit. Treating fruit with myoinositol obtained similar fruit phenotypes of SlIMP3-overexpressed fruit, with increased cell wall thickness and delayed fruit softening. Meanwhile, overexpression of SlIMP3 conferred tomato fruit tolerance to Botrytis cinerea. The function of SlIMP3 in cell wall biogenesis and fruit softening were also verified using another tomato species, Ailsa Craig (AC). Overexpression of SlDHAR in fruit increased AsA content, but did not affect the cell wall thickness or fruit firmness and softening. The results support a critical role for SlIMP3 in AsA biosynthesis and cell wall biogenesis, and provide a new method of delaying tomato fruit softening, and insight into the link between AsA and cell wall metabolism.

This study aimed to evaluate the therapeutic role of erythropoietin (EPO) or myoinositol versus metformin (MET) in improving the reproductive functions and glucose tolerance in a rat model of polycystic ovary (PCOS). Oral letrozole (LTZ) was used for induction of PCOS in wester rats for 21 days, after that, MET, EPO and myoinositol were administered for the following 21 days. The LTZ-induced PCOS rats have lost their oestrous cyclicity and become fixed at the diestrus phase, developed insulin resistance, abnormal sex and gonadotrophin hormone serum levels, increased cystic follicles, decreased number of the growing follicles and very little or no corpora lutea on microscopic examination, which were reversed by the three drugs, MET, EPO and myoinositol. MET and myoinositol were mostly equally effective in improving the reproductive manifestations of the disease. However, EPO was most effective in decreasing the insulin level observed in this LTZ-induced model of PCOS. [ABSTRACT FROM AUTHOR]

Polycystic ovary syndrome (PCOS) treatment in adolescents currently focuses on lifestyle interventions, with pharmacological treatment options often limited to hormonal contraceptives. Several of these carry broad side-effect profiles and are not always accepted by young girls. There is growing interest in non-hormonal therapies for PCOS. We aimed to collate the evidence on the use of myoinositol or D-chiro-inositol in the improvement of PCOS symptoms in symptomatic adolescents. A systematic literature review identifying key articles from inception to March 2023. Participants: Female adolescents (aged 12–19 years) with PCOS or PCOS-like features. Intervention: Myoinositol or D-chiro-inositol with or without additional interventions. Comparison: Any other treatment, including lifestyle interventions, hormonal therapy, metformin or no treatment. The main outcome measure were improvement in symptoms, quality of life and adverse effects. Eight studies were included: two randomised open-label trials, one quasi-randomised and three non-randomised interventional studies, one case-control study and one cohort study. All studies showed improvements in some biochemical markers, metabolic parameters or clinical symptoms, but these were not reproducible across all studies. The benefit of myoinositol in adolescents with PCOS remains unclear, with limited high-quality evidence. This review highlights the need for robustly conducted research to inform clinical practice. [ABSTRACT FROM AUTHOR]

Introduction: The prevalence of Polycystic Ovarian Syndrome (PCOS), one of the common endocrine disorders among women of reproductive age, varies from 2.2% to 26% globally. The treatment for PCOS aims to reduce Body Mass Index (BMI), improve underlying hormonal disturbances, prevent future reproductive and metabolic complications, and enhance the quality of life. Aim: To evaluate the efficacy of metformin and Myoinositol (MI) on the metabolic, hormonal, and clinical profiles in PCOS. Materials and Methods: An open-label randomised clinical trial was conducted at the Department of Obstetrics and Gynaecology, SRM Medical College Hospital and Research Centre, Kattankulathur, Chengelpet, Tamil Nadu, India, from January 2019 to May 2020. The study included 80 women with PCOS who were randomly assigned to two groups. One group received metformin 1500 mg/day (in three divided doses), while the other group received MI 1 gram/day for three months. At the end of the 12-week therapy, the participants were evaluated for changes in clinical, metabolic, and hormonal profiles. The data were analysed using Statistical Package for Social Sciences (SPSS) version 20.0. Descriptive statistics such as frequency, proportion, mean, and standard deviation were used for quantitative data. Results: Both the metformin and MI-treated groups showed a significant reduction in BMI, fasting blood glucose, and fasting insulin. Both drugs were equally effective in changing the hormonal profile. There was a significant improvement in lipid parameters in both groups, with High-density Lipoprotein (HDL) levels being more significantly raised in the metformin group. The post-treatment HDL values in the metformin group were 75.69±19.16 mg/dL compared to 41.43±6.18 mg/dL in the MI group (p<0.0001). Both groups demonstrated similar efficacy in improving menstrual regularity, with 60% of the patients in the metformin group and 65% in the MI group having regular cycles at the end of treatment. Among infertility patients, the conception rate was 40% in the metformin group and 25% in the MI group (p=0.70). Conclusion: Both drugs were equally efficient in improving the clinical, metabolic, and hormonal profiles in PCOS. Metformin was found to be superior to MI in improving fertility and increasing HDL levels. [ABSTRACT FROM AUTHOR]

Objective: Insulin resistance and hyperinsulinemia plays an important role in pathogenesis of polycystic ovary syndrome (PCOS). Metformin, Myoinositol and d‐chiro‐inositol acts as insulin sensitizers and exerts a beneficial effects in PCOS. The objective is to compare the effect of metformin monotherapy versus a combination of metformin with Myoinositol and d‐chiro‐inositol in PCOS. Design: This study is a randomized controlled trial conducted over a period of 6 months. All overweight and obese women with PCOS with the age group between 18 and 35 were included and randomized into two groups, 27 in the metformin monotherapy arm and 26 in the myoinositol combination arm. Patients and Measurements: The variables assessed were duration of menstrual cycle, anthropometric parameters, modified Ferriman Gallwey score, global acne score, Fasting insulin, HOMA‐IR, fasting lipid profile, serum testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, anti‐Mullerian hormone, and pelvic ultrasound to assess ovarian volume, PCOS Questionnaire score. Changes in the parameters from baseline at the end of 6 months of treatment were assessed and compared between the groups. Results: Menstrual cycle regularity improved in both groups with significantly greater improvement in the group receiving myoinositol‐based therapy (p <.001). Pregnancy rate was equal in both the arms. There was a significant improvement in PCOSQ score in myoinositol‐based therapy group (p <.001). However, there was no statistically significant difference in other hormonal, metabolic parameters between two groups in spite of symptomatic benefits. Conclusions: The addition of myoinositol to metformin exerts additional benefits in improving menstrual cycle regularity, and quality of life in women with PCOS. [ABSTRACT FROM AUTHOR]

Copyright of Al-Mustansiriyah Journal for Pharmaceutical Sciences is the property of Republic of Iraq Ministry of Higher Education & Scientific Research (MOHESR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introduction: Based on previous research on electroconvulsive therapy (ECT) we have proposed a model where disruption, potentiation, and rewiring of brain networks occur in sequence and serve as the underlying therapeutic mechanism of ECT. This model implies that a temporary disturbance of neuronal networks (disruption) is followed by a trophic effect (potentiation), which enables the rewiring of neuronal circuits to a more euthymic functioning brain. We hypothesized that disruption of neuronal networks could trigger biochemical alterations leading to a temporary decrease in N-acetylaspartate (tNAA, considered a marker of neuronal integrity), while choline (a membrane component), myo-Inositol (mI, astroglia marker), and glutamate/glutamine (Glx, excitatory neurotransmitter) were postulated to increase. Previous magnetic resonance spectroscopy studies, reporting diverse findings, have used two different referencing methods - creatine ratios and tissue corrected values referenced to water - for the quantification of brain metabolites. Changes in creatine during ECT have also been reported, which may confound estimates adopting this as an internal reference. Methods: Using MR spectroscopy, we investigated 31 moderately to severely depressed patients and 19 healthy controls before, during, and after ECT or at similar time points (for controls). We tested whether biochemical alterations in tNAA, choline, mI, and Glx lend support to the disrupt, potentiate, and rewire hypothesis. We used both creatine ratios and water-scaled values for the quantification of brain metabolites to validate the results across referencing methods. Results: Levels of tNAA in the anterior cingulate cortex decreased after an ECT treatment series (average 10.6 sessions) by 6% (p = 0.007, creatine ratio) and 3% (p = 0.02, water referenced) but returned to baseline 6 months after ECT. Compared to after treatment series tNAA levels at 6-month follow-up had increased in both creatine ratio (+6%, p < 0.001) and water referenced data (+7%, p < 0.001). Findings for other brain metabolites varied and could not be validated across referencing methods. Discussion: Our findings suggest that prior research must be interpreted with care, as several referencing and processing methods have been used in the past. Yet, the results for tNAA were robust across quantification methods and concur with relevant parts of the disrupt, potentiate, and rewire model. [ABSTRACT FROM AUTHOR]

Myoinositol (MI) and D-chiroinositol (DCI), used in the therapy of menstrual disorders, polycystic ovarian syndrome (PCOS), hirsutism, acne, gestational diabetes, and other diseases, are required for intracellular signal transduction from insulin and other hormone receptors. Clinical practice shows that, for instance, MI and DCI in the treatment of PCOS improve the condition of skin, hair, and nails. These effects of MI and DCI are related to the normalization of insulin signaling and support of differentiation and growth of various skin cell types (keratinocytes, fibroblasts, epitheliocytes, etc.). The effects of MI and DCI on the skin and its appendages, including in wound healing, can be enhanced by manganese, which provides an antioxidant effect and improves the connective tissue matrix of the skin, and folic acid, which is involved in amino acid metabolism, proliferation, and differentiation of dividing cells.

Background: The delay and increase in the number of Alzheimer's dementia patients cause many impacts, both from increased morbidity and moral and material losses. Biomarkers such as brain imaging (magnetic resonance imaging (MRI) and positron emission tomography (PET) Scan) need to be done immediately in the diagnosis of suspected Alzheimer's dementia. This study aimed to analyze the relationship between the hippocampal myo-inositol (MI)/ N-acetylaspartate (NAA) ratio and the severity of Mini-Mental State Examination (MMSE) in Alzheimer's dementia patients. Methods: MMSE and Hachinski scores were assessed by a neurologist, and the hippocampal mI/NAA ratio was calculated using MRI and MR spectroscopy. Results: The right hippocampal MI/NAA was significant with the incidence of Alzheimer's (p value = 0.018). Conclusion: There was a correlation between right MI/NAA and the severity of MMSE in Alzheimer's dementia patients. [ABSTRACT FROM AUTHOR]

IntroductionBased on previous research on electroconvulsive therapy (ECT) we have proposed a model where disruption, potentiation, and rewiring of brain networks occur in sequence and serve as the underlying therapeutic mechanism of ECT. This model implies that a temporary disturbance of neuronal networks (disruption) is followed by a trophic effect (potentiation), which enables the rewiring of neuronal circuits to a more euthymic functioning brain. We hypothesized that disruption of neuronal networks could trigger biochemical alterations leading to a temporary decrease in N-acetylaspartate (tNAA, considered a marker of neuronal integrity), while choline (a membrane component), myo-Inositol (mI, astroglia marker), and glutamate/glutamine (Glx, excitatory neurotransmitter) were postulated to increase. Previous magnetic resonance spectroscopy studies, reporting diverse findings, have used two different referencing methods - creatine ratios and tissue corrected values referenced to water – for the quantification of brain metabolites. Changes in creatine during ECT have also been reported, which may confound estimates adopting this as an internal reference.MethodsUsing MR spectroscopy, we investigated 31 moderately to severely depressed patients and 19 healthy controls before, during, and after ECT or at similar time points (for controls). We tested whether biochemical alterations in tNAA, choline, mI, and Glx lend support to the disrupt, potentiate, and rewire hypothesis. We used both creatine ratios and water-scaled values for the quantification of brain metabolites to validate the results across referencing methods.ResultsLevels of tNAA in the anterior cingulate cortex decreased after an ECT treatment series (average 10.6 sessions) by 6% (p = 0.007, creatine ratio) and 3% (p = 0.02, water referenced) but returned to baseline 6 months after ECT. Compared to after treatment series tNAA levels at 6-month follow-up had increased in both creatine ratio (+6%, p

Background: The purpose of this study was to evaluate the effects of Coenzyme Q10, Myo-Inositol, Astaxanthin, and L-Arginine levels in the follicular fluid obtained during serum and oocyte collection on oocyte maturation, fertilization, and pregnancy outcomes. Additionally, we aimed to assess the correlation between serum and follicular fluid levels and other parameters simultaneously. If significant results are obtained, an affordable and easily accessible test that predicts the success of assisted reproductive technology will be found, resulting in higher treatment success rates and healthier pregnancies. Materials and Methods: We measured Coenzyme Q10, Myo-Inositol, Astaxanthin, and L-Arginine values in the serum on Day-3 and OPU days, as well as the follicular fluids collected from 60 patients who underwent IVF protocol at our clinic between October 2021 and October 2022. We statistically evaluated the relationship between Coenzyme Q10, Myoinositol, Astaxanthin, and L-Arginine levels with oocyte maturation, fertilization, and pregnancy outcomes. Results: We found no correlation between the number of mature oocytes and fertilized oocytes and the values of Coenzyme Q10, Myo-Inositol, Astaxanthin, and L-Arginine measured from serum and follicle (p>0.05). A negative correlation was observed between total gonadotropin doses and the number of collected oocytes, mature oocytes, and fertilized oocytes (p<0.05). There was no significant difference in the serum taken on the 3rd day of the follicular phase, in the serum on the day of oocyte retrieval, and in Coenzyme Q10, Myo-Inositol, and L-Arginine values measured from the follicle between pregnant and non-pregnant women (p>0.05). When the Astaxanthin value measured in the serum on the 3rd day of the follicular phase was < 0.3035, the probability of pregnancy was found to be higher. No significant difference was found between clinical pregnancy and biochemical pregnancy in Coenzyme Q10, Astaxanthin, and L-Arginine values measured in the serum taken on the 3rd day of the follicular phase, in the serum on the day of oocyte retrieval, and in the follicle (p>0.05). The possibility of biochemical pregnancy was found to be higher when the Myo-Inositol value measured in serum on the day of oocyte retrieval was > 1.6555. Conclusions: For stronger results of our research hypothesis, studies with larger patient populations are needed. [ABSTRACT FROM AUTHOR]

Purpose: The present study aimed to assess whether treatment with combined resveratrol and myoinositol is more effective in ameliorating the altered parameters associated with PCOS when compared to the combined metformin and pioglitazone therapy. Method: One hundred and ten obese, oligo-anovulatory PCOS women, aged 20–35 years were randomly assigned into two treatment arms. Participants in arm-1 (n = 55), received combination of metformin and pioglitazone (500 mg and 15 mg, respectively), twice daily, while those in arm-2 (n = 55) received combination of resveratrol and myoinositol (1000 mg and 1000 mg, respectively) twice daily for 12 weeks. Evaluations performed at baseline were repeated after 3 months of therapy. The endocrine and metabolic derangements were assessed by measuring serum levels of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), adiponectin and insulin using ELISA. Cohen's perceived stress scale (PSS) was employed as a subjective measure of stress. Results: Pre-treatment PCOS women in both the arms (arm-1 and arm-2) had remarkably elevated serum testosterone and insulin concentrations, low serum adiponectin and high perceived stress response scores. The treatment reduced the altered endocrine indices in arm-2 (resveratrol and myoinositol) participants, manifested by statistically significant reduction in serum testosterone level (p = 0.001) and notably increased serum adiponectin level (p = 0.001). Interestingly, the hormonal profile, including serum LH and FSH levels also decreased (p < 0.001) along with a marked reduction in the ovarian volume (p = 0.001) in arm-2 participants. There was a significant reduction in weight (<0.001), BMI (p < 0.001) and an improvement in waist-hip ratio (p < 0.001) in arm-2 participants compared to arm-1 group. The PSS scores of the arm-2 subjects improved significantly (p < 0.001) whereas, the Ferrimen-Gallwey score was improved in both the arms (arm-1 and arm-2; p = 0.010 and 0.008 respectively) however, the change was highly significant in arm-2. Interestingly, the menstrual regularity was 81.4% in arm-2 while 18.2% in arm-1. We conclude that the therapeutic intervention with combined resveratrol and myoinositol is more effective in ameliorating altered endocrine, metabolic indices and stress burden and could be of clinical importance in high risk group of obese, oligo-anovulatory married PCOS affected women. Trial registration: ClinicalTials.gov Trial No: NCT04867252. Registered 24 April, 2021, https://clinicaltrials.gov/ct2/show/NCT04867252 [ABSTRACT FROM AUTHOR]

Polycystic ovary syndrome (PCOS) is associated with insulin resistance. Few randomized controlled trials (RCT) compared myoinositol (MI) with metformin (MET) regarding insulin resistance in PCOS. This was an open-label six-month RCT in women with PCOS (n = 45) with interventions MI 4 g/day or MET 2 g/day. Primary outcome was the homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes were fasting glucose, weight, cycle length, lipids, testosterone, adverse effects, quality of life, and depression scores. Median age was 26 years. Body mass was index was 34.4 kg/m2. HOMA-IR was unchanged during MI (p = 0.31) and MET (p = 0.11) (MI vs. MET, p = 0.09). Median fasting glucose changed +0.2 mmol/L during MI (p < 0.001) and −0.1 mmol/L during MET (p = 0.04) (MI vs. MET p < 0.001). Median weight changed −2.3 kg during MI (p = 0.98) and −6.1 kg during MET (p < 0.001) (MI vs. MET, p = 0.02). Median cycle length decreased nine days during MI (p = 0.03) and 13 days during MET (p = 0.03) (MI vs. MET, p = 0.93). High-density lipoprotein (HDL) changed +0.1 mmol/L during MET (p = 0.04) (MI vs. MET, p = 0.07). All other blood parameters and scores of quality of life and depression remained unchanged during MI and MET (all p > 0.06) (MI vs. MET, all p > 0.27). Adverse effects appeared in four women during MI and 16 women during MET (MI vs. MET, p = 0.001). In conclusion, there was no effect on the metabolic outcomes during MI, but positive effects on fasting blood glucose, weight, and HDL during MET. The effect on cycle length was comparable during MI and MET. Adverse effects were less frequent during MI. [ABSTRACT FROM AUTHOR]

Aim. Effect of daily use of the combination of myoinositol and D-chiroinositol with manganese and folic acid (Dikirogen) on the onset of a regular menstrual cycle, ovulation, pregnancy, tolerance and satisfaction of the study participants. Materials and methods. The study involved 60 women aged 40 years and younger, the average age was 30,933,79 years. Duration of taking Dikirogen was 1703 days, participants observation was 1803 days. Body mass index, waist circumference (WC), ultrasound of the pelvic organs and ovaries, assessment of hirsutism (Ferryman-Gallway scale), acne severity (Cook questionnaire), depressive symptoms (Hamilton scale), quality of life (SF36 questionnaire) were performed during the study. Results. The pregnancy rate at the end of the study was 31.7%. During the daily using of the Dikirogen, there was a decrease in WC (p=0,007), the severity of acne (p=0,002) and the number of points on the Hamilton scale (p=0,04). Also there was a increase in the number of points on the SF36 questionnaire (p=0,0001). 93.33% of the woman has been reported that the Dikirogen was well tolerated. Conclusion. Dikirogen is an optimal doses chemical composition, selected taking into account the synergism of the components and the daily requirement, and it is effective in treatment for women with anovulatory infertility.

People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD). Neuropathology consistent with AD is present by 40 years of age and dementia may develop up to a decade later. In this review, we describe metabolic and vascular neuroimaging studies in DS that suggest these functional changes are a key feature of aging, linked to cognitive decline and AD in this vulnerable cohort. FDG-PET imaging in DS suggests systematic reductions in glucose metabolism in posterior cingulate and parietotemporal cortex. Magentic resonance spectroscopy studies show consistent decreases in neuronal health and increased myoinositol, suggesting inflammation. There are few vascular imaging studies in DS suggesting a gap in our knowledge. Future studies would benefit from longitudinal measures and combining various imaging approaches to identify early signs of dementia in DS that may be amenable to intervention.

In this study, the influence of myoinositol (MYO) as an antioxidant on the inhibition of the negative impacts of cryopreservation on sperm quality in men with Asthenospermia was investigated. In this prospective study, each semen sample from 25 cases was separated into three groups: Fresh, Control (with freezing medium), Myoinositol (2 mg/ml). According to the World Health Organization criteria (WHO) (2010), total motility, progressive sperm motility, viability, normal morphology, and DNA integrity were assessed. In addition, the hypo‐osmotic swelling (HOS) test and mitochondrial membrane potential (MMP) were used. Total antioxidant capacity (TAC), malondialdehyde (MDA), and antioxidant enzyme activity were determined by the ELISA method. In contrast to the fresh samples, lipid peroxidation, DNA integrity damage, DNA fragmentation, HOST, and MMP had significant enhancement in the control samples. Sperm quality was significantly decreased (p < 0.05). Mean percentage viability, normal morphology, total motility, progressive motility, and DNA integrity were significantly enhanced in the MYO group in comparison to the control group (p < 0.05). The MDA and TAC levels and DNA damage in the MYO group were significantly lower compared to the control group (p < 0.05). The findings confirm that sperm quality in patients with Asthenospermia is improved by the administration of 2 mg/ml of myoinositol together with the freezing medium after sperm cryopreservation. [ABSTRACT FROM AUTHOR]

Objective: Earlier work suggests Myoinositol (MI) and D-chiro- inositol (DCI) imbalance in urine and plasma of diabetic patients, and their potential for monitoring insulin resistance. This study aimed to assess levels of Myoinositol (MI) and D-chiro- inositol (DCI) in saliva of children with type 1 diabetes mellitus (DM-1) and controls, to verify if concentrations of MI and DCI are similarly altered in saliva, exploring their potential for monitoring DM-1., Design, Patients and Measurements: This cross-sectional clinical study enroled 45 patients (DM-1, n = 25; Controls, n = 20). Children aged 3-12 years with fasting blood glucose levels > 126 mg/dL, and HbA1c levels > 7%. Saliva was collected, and salivary measurements included pH, flow rates and concentrations of MI, DCI and glucose, employing high-performance liquid chromatography. Periodontal health was assessed using bleeding and plaque indices., Results: Children with DM-1 showed elevated MI (p = 0.001), reduced DCI (p = 0.001), and increased MI-DCI ratio (p = 0.001). The MI-DCI ratio was elevated by 16-fold among diabetic children. Plaque (p = 0.003) and gingival bleeding (p = 0.001) were higher in DM-1 than controls. The MI increased the odds of an outcome of DM-1 by 174%, while DCI reduced the odds by 63%, highlighting their strong and opposing effects on DM-1., Conclusions: Children with DM-1 express higher MI and lower DCI levels, while non-diabetic children show an inversion of these concentrations. Inositol imbalance in saliva of diabetic children resembles previous results in urine, and represents a possible venue for monitoring this disease, paving the way for future investigations into salivary inositols., (© 2024 John Wiley & Sons Ltd.)

Background. Abnormal uterine bleeding (AUB) occurs in one-third of women of reproductive age and has a significant impact on women's lives, causing anemia, impaired social adaptation and professional activity. AUB-O (ovulatory dysfunction) is often caused by an excessive body mass (BM) and obesity (especially visceral). The most effective option for restoring menstrual cycle (MC) in obese women is BM reduction. There is evidence that the combination of inositols myoinositol (MI) and D-chiroinositol (DCI) has a beneficial effect on BM loss, ovulation frequency and getting pregnant in women with polycystic ovary syndrome. Aim. To study the effect of MI and DHI in a 5:1 ratio in combination with diet and exercise on the regulation of MC in overweight and obese women. Materials and methods. The study has been conducted in clinics of Moscow, Kazan and Tyumen for 20202021. It is a descriptive study assessing an efficacy of lifestyle modification (diet and exercise) plus a nutritional support with a combination of 1000 mg MI and 200 mg DCI (ratio 5:1) for 24 months in 353 women of reproductive age with AMK-O and overweight or obesity. Efficacy criteria include: MC regularity, BM index (BMI), waist circumference (WC), levels of serum glucose, free testosterone, follicle-stimulating hormone, luteinizing hormone. Results. The study showed a significant shortening of MC to its physiological duration 3112.04 days (vs 4419.51 days at the 1st visit; p=0.001), a decrease in the rate of heavy bloody vaginal discharge by 2.57 times (p=0.001), an increase in the rate of moderate bloody vaginal discharge by 1,62 times (p=0.001), an increase in the proportion of patients with regular MC by 2.69 times (p=0.001). These changes were accompanied by a decrease in BM (-3 kg; p=0.001), a decrease in WC (-2.5 cm; p=0.001). Laboratory tests revealed a decrease in serum glucose (-1.3 mmol/L; p0.05), free testosterone (-0.4 pg/L; p0.05), luteinizing hormone (-0.8 mIU/ml; p0.05), and an increase in follicle-stimulating hormone (+0.1 mIU/ml; p0.05) levels. Conclusion. The results obtained (a decrease in BM, a decrease in BMI, WC, as well as MC restoration; p0.05) make it possible to recommend Dikirogen containing MI and DCI in a 5:1 ratio as a part of comprehensive therapy for overweight and obese women with AUB-O.

Introduction: Myo-inositol (MYO) and D-chiro-inositol are chemical compounds known to exert an impact on multiple signaling pathways of a human body. Due to its effects on insulin metabolism and ovaries’ hormone activity their use in polycystic ovary syndrome (PCOS) therapies has been highly recommended in the recent literature. In this article we aim to review the known and possible applications of inositol and its derivatives for treatment of various gynecological and endocrine disorders and to indicate possible directions of further investigations. Methods and materials: This article is based on the literature found in PubMed Database from the period of 2016-2022 with use of keywords such as “inositol”; “myoinositol”; “d-chiro-inositol”; “PCOS”; “insulin”. Results: The applications of myoinositol in the treatment of polycystic ovary syndrome (PCOS) are very well known in recent publications. It is reported that MYO supplementation improves the quality of oocytes, regulates the menstrual cycle and ovulation rates. Prevention of gestational diabetes (GDM) amongst the patients with risk factors is likely another use of inositols. Inositol takes part in phospholipase C pathway, thus its depletion may be the cause for hypothyroidism. Inositol inhibits the expression of aromatase, the enzyme which is responsible for the growth of endometrial tissue - it may constitute a targeting point in the treatment of endometriosis. So far, no adverse effects of inositol isomers have been reported. Conclusion: The use of inositol, its isomers and derivatives represents an interesting direction in the development of the treatment of many conditions associated with endocrine disorders. There is a need for further investigations and studies on larger groups of patients to exploit its potential.

Background: Myo-inositol is an intracellular mediator which is involved in various aspects of reproduction in women. Objective: This study aimed to evaluate the impact of Myo-inositol on the outcomes of in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles in infertile women. Materials and Methods: This double-blind randomized controlled trial was conducted on 70 infertile women referred to the Infertility Treatment Center, Besat hospital, Sanandaj, Iran from May 2019 to September 2019 for IVF/ICSI cycles. The participants were randomly divided into 2 intervention (n = 36) and control (n = 34) groups. The intervention group received 2000 mg of Myo-inositol and 200 mcg folic acid twice a day for 2 months and the control group received 200 mcg of folic acid twice a day for 2 months in the IVF/ICSI cycles (from the third day of cycle until the end of the second month). Finally, the number of oocytes, the quality of embryos, and the IVF/ICSI outcomes were compared between the 2 groups. Results: The mean numbers of oocytes, MII oocytes, and 2 pronuclear embryos were significantly higher in the intervention group than the control group. Also, the clinical pregnancy and live birth rates in the intervention group were significantly higher than in the controls (p = 0.04). Conclusion: The administration of Myo-inositol may increase clinical pregnancy and live birth rates by increasing the number of total and meiosis II oocytes in infertile women undergoing IVF/ICSI. [ABSTRACT FROM AUTHOR]

Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. Myo is mainly derived from dietary intake while its endogenous production is generated from glucose by enzymatic reactions. Moreover, Myo is also synthesized de novo by catabolism of phosphatidylinositol (PI), phosphoinositides (PIP), and inositol phosphates (IP). Myo has a determinant role in thyroid function and autoimmune diseases as it regulates iodine organification and thyroid hormone biosynthesis by the formation of hydrogen peroxide (H2O2) in thyrocytes. Depletion of Myo that is involved in the thyroid stimulating hormone (TSH) signaling pathway, may cause the development of thyroid diseases such as hypothyroidism. TSH levels significantly decreased in patients with subclinical hypothyroidism, with or without autoimmune thyroiditis, after treatment with Myo plus Selenium (Myo+Se). In addition to TSH, antithyroid autoantibodies are reduced. This review summarizes the role of Myo in the thyroidal physiology and its role in the management of some thyroid diseases. [ABSTRACT FROM AUTHOR]

Papillary tumor of the pineal region (PTPR) is an uncommon entity in which a presurgical suspicion may be crucial for patient management. Maximal safe neurosurgical resection is of choice when PTPR is suspected, whereas non-surgical approaches can be considered in other tumors of the pineal region, such as pineocytoma or concrete subtypes of germ-cell tumors. In general terms, imaging features of tumors of the pineal region have been reported to be unspecific. Nevertheless, in this report, we describe two pathology-confirmed PTPRs in which presurgical proton MR spectroscopy demonstrated extremely high myoinositol, a pattern which drastically differs from that of other pineal tumors. We hypothesize that this high myoinositol may be related to PTPR's known ependymal component, and that it could be used as a specific non-invasive diagnostic signature. [ABSTRACT FROM AUTHOR]

Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. Myo is mainly derived from dietary intake while its endogenous production is generated from glucose by enzymatic reactions. Moreover, Myo is also synthesized de novo by catabolism of phosphatidylinositol (PI), phosphoinositides (PIP), and inositol phosphates (IP). Myo has a determinant role in thyroid function and autoimmune diseases as it regulates iodine organification and thyroid hormone biosynthesis by the formation of hydrogen peroxide (H2O2) in thyrocytes. Depletion of Myo that is involved in the thyroid stimulating hormone (TSH) signaling pathway, may cause the development of thyroid diseases such as hypothyroidism. TSH levels significantly decreased in patients with subclinical hypothyroidism, with or without autoimmune thyroiditis, after treatment with Myo plus Selenium (Myo+Se). In addition to TSH, antithyroid autoantibodies are reduced. This review summarizes the role of Myo in the thyroidal physiology and its role in the management of some thyroid diseases.

PCOS is a metabolic syndrome that has affected millions of women as it is a mysterious disease with a very complex aetiology with no cure to date. It is a lifestyle disorder that requires holistic treatment. Hormonal therapy, supplements, and surgical approaches are not the answer for all cases. This paper review's introduction and implementation of complementary and alternative medicine (CAM), immunotherapy, vitamin supplementations, diet therapy, oxygen therapy and traditional Chinese medicine (TCM) as a primary mode in the management of PCOS. [ABSTRACT FROM AUTHOR]

To determine if proton magnetic resonance spectroscopy ((1)H-MRS) detect differences in dementia status in adults with Down syndrome (DS), we used (1)H-MRS to measure neuronal and glial metabolites in the posterior cingulate cortex in 22 adults with DS and in 15 age- and gender-matched healthy controls. We evaluated associations between (1)H-MRS results and cognition among DS participants. Neuronal biomarkers, including N-acetylaspartate (NAA) and glutamate-glutamine complex (Glx), were significantly lower in DS patients with Alzheimer's should probably be changed to Alzheimer (without ' or s) through ms as per the new naming standard disease (DSAD) when compared to non-demented DS (DS) and healthy controls (CTL). Neuronal biomarkers therefore appear to reflect dementia status in DS. In contrast, all DS participants had significantly higher myo-inositol (MI), a putative glial biomarker, compared to CTL. Our data indicate that there may be an overall higher glial inflammatory component in DS compared to CTL prior to and possibly independent of developing dementia. When computing the NAA to MI ratio, we found that presence or absence of dementia could be distinguished in DS. NAA, Glx, and NAA/MI in all DS participants were correlated with scores from the Brief Praxis Test and the Severe Impairment Battery. (1)H-MRS may be a useful diagnostic tool in future longitudinal studies to measure AD progression in persons with DS. In particular, NAA and the NAA/MI ratio is sensitive to the functional status of adults with DS, including prior to dementia.

To study the effects of myoinositol (Myo) in comparison to metformin (Met), in reducing the risk of OHSS and improving ART outcome in PCOS women undergoing IVF. Double-blinded randomized controlled trial (CTRI/2018/05/014196). ART Clinic, AIIMS, New Delhi patients: 102 infertile PCOS women undergoing IVF cycles were enrolled after evaluating for eligibility and allotted as 50 in group 1 (Myo) and 52 in group 2 (Met) after randomization. Recruited patients received Myo 2 g twice daily (group 1) and Met 850 mg twice daily (group 2). Pre- and post-treatment clinical (menstrual pattern, BMI), hormonal profile (LH, FSH, testosterone, prolactin [PRL], and AMH), biochemical parameters (HOMA IR, fasting glucose, and insulin), ovarian with antral follicle count (AFC) and side effect profile were assessed. After 3 months of therapy, patients were recruited for IVF cycle by antagonist protocol was involving controlled ovarian stimulation, cycle monitoring, oocyte recovery, insemination of oocytes and follow up with fertilization, cleavage, transfer of good grade cleavage embryos, or blastocysts pregnancy outcomes and OHSS incidence and medications was continued until the day of OPU. Primary outcome was OHSS and clinical pregnancy rate including spontaneous, IVF, and cumulative pregnancy rate including FET. Secondary outcome was ART outcomes and the change in biochemistry and hormonal profile between groups and inter group after medications at 12 weeks. Incidence of OHSS (Myo 5 (10.0) (n = 50), Met 10 (20.0) (n = 50) p.07) was not statistically different between groups. Clinical pregnancy rate (Myo 18 (36.0) (n = 50), Met 9 (18.0) (n = 50) p.04) cumulative pregnancy rate including FET (Myo 16 (43.2) (n = 37) vs. Met 10) 22.7) (n = 44) p.05) and spontaneous conception (prior to IVF) Myo 13 (26.0) (n = 50), Met 6 (12.0) (n = 50) p.07) was significantly high in Myo group. No between group difference in ovarian stimulation outcomes including duration and dosage of gonadotropins, E2, P4 levels, number of follicles >14 mm on day of trigger. Number of oocytes retrieved and grade of maturity were similar between groups. Fertilization, cleavage and number of good grade embryos were significantly higher in Myo group. However, implantation rate and number of embryos for freezing were similar between groups. Myo had improvement in fasting insulin, HOMA, Sr.AMH, and SHBG suggesting decreased insulin resistance Myo is equally beneficial as Met in reducing the risk of OHSS and has better ART outcome in PCOS women undergoing antagonist cycles. [ABSTRACT FROM AUTHOR]

This study was conducted to determine effects of high phytase use on growth performance, amino acid (AA) digestibility, intestinal phytate breakdown, and nutrient transporter expression in starter broiler chickens. Male Ross 308 chicks were allocated to 24 pens, at 15 birds/pen and assigned to one of 4 dietary treatments. Treatments were: a control diet (PCa+) that contained adequate levels of calcium (Ca) and phosphorus (P) for growing broiler chicks; a reduced Ca and P diet (PCa–:–1.5 g P/kg and –1.6 g Ca/kg), and 2 additional diets in which phytase was supplemented in the PCa– diet at 1,500 (PCa-Phy1500) and 3,000 (PCa-Phy3000) FTU/kg feed. A common starter diet was fed from day 1 to 8. From day 8 to 22, birds were fed the 4 experimental diets. On day 22, birds were killed for sample collection. From day 8 to 15, average daily gain and average daily feed intake were not different across treatments (P < 0.05) but gain-to-feed ratio (G:F) was reduced (P < 0.006) in the PCa– treatment compared with other treatments. There were no further performance differences, but a tendency of phytase treatments improving the overall G:F (P = 0.079; day 8–22). Up to both the duodenum–jejunum and ileum, phytate, P, and Ca disappearance were increased (P < 0.05) in the PCa-Phy1500 and PCa-Phy3000 treatments compared with PCa– treatment. Phytase dose dependently increased myoinositol (MI) concentration in the digesta from both the duodenum–jejunum and ileum (P < 0.001). The highest concentration of MI was found in the PCa-Phy3000 treatment. Plasma MI concentration was increased by phytase supplementation (P

Polycystic ovary syndrome (PCOS) is associated with insulin resistance. Few randomized controlled trials (RCT) compared myoinositol (MI) with metformin (MET) regarding insulin resistance in PCOS. This was an open-label six-month RCT in women with PCOS (n = 45) with interventions MI 4 g/day or MET 2 g/day. Primary outcome was the homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes were fasting glucose, weight, cycle length, lipids, testosterone, adverse effects, quality of life, and depression scores. Median age was 26 years. Body mass was index was 34.4 kg/m2. HOMA-IR was unchanged during MI (p = 0.31) and MET (p = 0.11) (MI vs. MET, p = 0.09). Median fasting glucose changed +0.2 mmol/L during MI (p < 0.001) and −0.1 mmol/L during MET (p = 0.04) (MI vs. MET p < 0.001). Median weight changed −2.3 kg during MI (p = 0.98) and −6.1 kg during MET (p < 0.001) (MI vs. MET, p = 0.02). Median cycle length decreased nine days during MI (p = 0.03) and 13 days during MET (p = 0.03) (MI vs. MET, p = 0.93). High-density lipoprotein (HDL) changed +0.1 mmol/L during MET (p = 0.04) (MI vs. MET, p = 0.07). All other blood parameters and scores of quality of life and depression remained unchanged during MI and MET (all p > 0.06) (MI vs. MET, all p > 0.27). Adverse effects appeared in four women during MI and 16 women during MET (MI vs. MET, p = 0.001). In conclusion, there was no effect on the metabolic outcomes during MI, but positive effects on fasting blood glucose, weight, and HDL during MET. The effect on cycle length was comparable during MI and MET. Adverse effects were less frequent during MI.

The deficit syndrome is thought to be a more homogenous clinical subgroup within the syndrome of schizophrenia that is characterized by enduring negative symptoms. It is hypothesized that distinct pathophysiological processes underlie the subtypes, where the deficit syndrome reflects an early onset nonprogressive developmental process, and the nondeficit form of the illness is characterized by attenuated neuroplasticity secondary to elevated glutamate levels. We used single-voxel magnetic resonance spectroscopy (PRESS; TE: 30 ms) to measure left frontal white matter neurometabolite levels in 61 antipsychotic-naïve first-episode psychosis patients (39 who did not display deficit features, 22 who did display deficit features, assessed with the Schedule for the Deficit Syndrome) and 59 healthy controls. Metabolite levels were quantified with the LCModel. We used a MANCOVA to determine neurometabolite differences between healthy controls, deficit syndrome patients, and nondeficit patients. We report a significant group difference when all metabolites were considered jointly (F [10,208] = 2.16; P =.02). Post hoc analyses showed that patients presenting without deficit features had higher glutamate levels than patients with deficit features and controls. Patients presenting without deficit features also had significantly higher myoinositol levels than controls; myoinositol levels were trend-level higher in patients presenting with deficit features compared to controls. Our data support the idea that the pathophysiology of patients presenting without deficit features may differ from those presenting with deficit features. [ABSTRACT FROM AUTHOR]

To investigate the impact of myoinositol (MI) immersion treatment on the storage characteristics of Prunus salicina 'Wushan Plum', we assessed myoinositol content, ascorbic acid content, weight loss, decay rate, alteration in color, titratable acidity (TA), soluble solids (TSS), firmness, cell wall metabolism-related compounds, enzyme activities, and levels of gene expression throughout a 15-day storage period at 25 °C. The results revealed that MI treatment could increase myoinositol and ascorbic acid contents of fruit during the pre-storage period, effectively delay the color transformation and decay progression of P. salicina 'Wushan Plum' while maintaining elevated levels of TA and TSS. Furthermore, it suppressed the increase in weight loss and the decline in firmness. Notably, the delay in softening was more pronounced in the group treated with 100 mg L−1 MI compared to other groups. MI treatment regulated the expression levels of various genes associated with cell wall metabolism, which resulted in reduced activities of polygalacturonase (PG), pectate lyase (PL), pectin methylesterase (PME), cellulase (Cx), and β-glucosidase (β-Glu), and increased activities of phenylalanine ammonia-lyase (PAL) and cinnamyl alcohol dehydrogenase (CAD). Furthermore, MI treatment maintained higher levels of covalently bound pectin (CSP), cellulose, and lignin, while decreasing the levels of water-soluble pectin (WSP) in the fruit. As a result, MI treatment could delay the depolymerization of cell wall polysaccharides and further delay the quality deterioration of P. salicina 'Wushan Plum' fruits under ambient storage environment and prolong the storage period. • Myoinositol (MI) treatment delays plum fruit post-ripening. • MI treatment increases plum myoinositol and ascorbic acid content. • MI treatment delays plum fruit softening by regulating cell wall metabolism. • MI may be an environmentally friendly and effective preservative of plum fruit. [ABSTRACT FROM AUTHOR]

The objective of this study was to investigate the effects of increasing doses of a hybrid bacterial 6-phytase on apparent total tract digestibility (ATTD) of energy and nutrients, plasma level of free myoinositol, retention of calcium (Ca) and phosphorus (P), and growth performance of growing pigs fed Ca and P deficient diets. A total of 15 barrows [21.5 ± 1.4 kg BW; Duroc × (Landrace × Yorkshire)] were allotted to a triplicated 5 × 5 Latin square design with 5 dietary treatments and 5 periods per each square. Pigs were individually housed in a metabolism crate. Five dietary treatments consisted of 5 levels of phytase (0, 500, 1000, 1500, and 2000 FTU/kg) supplemented to a basal diet containing nutrients meeting the requirement except for Ca and P. The basal diet was deficient in total Ca and P by 2.2 and 1.7 g/kg below the recommendations from NRC, respectively. Data were analyzed using orthogonal polynomial contrasts using Proc MIXED of SAS and the optimal phytase levels were determined by a broken line analysis using Proc NLMIXED. Increasing phytase supplementation increased (linear: P < 0.01; quadratic: P < 0.01) ATTD of Ca and P and retention of Ca and P. Increasing phytase supplementation increased (linear: P < 0.05; quadratic: P < 0.05) myoinositol contents in plasma. Based on broken line analyses, ATTD of Ca and retention of Ca were increased until phytase supplementation were increased from 0 to 668 ± 65 FTU/kg (P < 0.01) and 0 to 668 ± 69 FTU/kg (P < 0.01), respectively. The ATTD of P and retention of P were increased until phytase supplementation contents were increased from 0 to 780 ± 86 FTU/kg (P < 0.01) and 0 to 773 ± 93 FTU/kg (P < 0.01), respectively. Myoinositol contents in plasma were increased (11.4 to 22.8 µmol/L) until phytase supplementation were increased from 0 to 705 ± 212 FTU/kg (P < 0.05). Increasing phytase supplementation linearly increased (P < 0.05) average daily gain and tended to linearly increase (P = 0.053) gain to feed ratio. In conclusion, supplementation of a hybrid bacterial 6-phytase improved ATTD of Ca and P, retention of Ca and P, complete hydrolysis of phytate, and growth performance of pigs compared with pigs fed a Ca and P deficient basal diet. Supplementation of a hybrid bacterial 6-phytase at a range of 650 to 800 FTU/kg feeds provided the optimal improvement of Ca, P, and phytate utilization. • Hybrid bacterial 6-phytase increased plasma myoinositol • Hybrid bacterial 6-phytase improved Ca and P utilization and growth of pigs • Hybrid bacterial 6-phytase at 650 to 800 FTU/kg provided optimal Ca and P improvement [ABSTRACT FROM AUTHOR]

Myoinositol is the basis for the synthesis of an important group of signal molecules, inositolphosphates, which mediate signal transmission from receptors of growth factors and neurotransmitters. Grants myo-Inositol promote the prevention of folate-resistant defects and neuroprotection of the fetal brain ischemia. The paper presents the results of a study of the effects of myoinositol on the growth of cerebellar neurons in culture under glutamate stress. It is shown that the effects of myoinositol on the survival of neurons (+17 %) exceed the effects of drugs that are usually used for neuroprotection (peptide extracts - + 10 %, choline preparations - no more than 3 %). Confirmed in the present work, a direct neuroprotective effect of myo-Inositol indicates the importance of the use of myo-Inositol during pregnancy with the aim of neuroprotection of the fetal brain.

Polycystic Ovarian Syndrome (PCOS) is one of the most common metabolic and reproductive ailment among reproductive age group women. PCOS patients present with a constellation of signs and symptoms associated with menstrual dysfunction and androgen excess, which significantly impacts quality of life. Women with PCOS is at increased risk of various morbidities, which includes obesity, insulin resistance, type II diabetes mellitus, cardiovascular disease (CVD), infertility, cancer, and psychological disorders. Exact pathophysiology of PCOS is poorly understood although studies have suggested an important role of insulin resistance and/or resultant compensatory hyperinsulinemia. Deficiency in the usage and/or tissue availability of myoinositol (MI) and/or D-chiroinositol (DCI) in PCOS patients could likely lead to insulin resistance typical of this syndrome. Recent studies have demonstrated that combined supplement containing both MI + DCI in their physiological plasma ratio 40:1 is able to improve the endocrine profile, ovarian function and the insulin resistance in PCOS patients. The aim of the present review was to summarize currently available data on the MI+DCI (40:1) combination therapy in PCOS patients.

Papillary tumor of the pineal region (PTPR) is an uncommon entity in which a presurgical suspicion may be crucial for patient management. Maximal safe neurosurgical resection is of choice when PTPR is suspected, whereas non-surgical approaches can be considered in other tumors of the pineal region, such as pineocytoma or concrete subtypes of germ-cell tumors. In general terms, imaging features of tumors of the pineal region have been reported to be unspecific. Nevertheless, in this report, we describe two pathology-confirmed PTPRs in which presurgical proton MR spectroscopy demonstrated extremely high myoinositol, a pattern which drastically differs from that of other pineal tumors. We hypothesize that this high myoinositol may be related to PTPR’s known ependymal component, and that it could be used as a specific non-invasive diagnostic signature.

Objective: To compare efficacy of myoinositol as an adjuvant to dietary modification for treatment of gestational diabetes mellitus in Asian Indian women compared to controls.Study Design: Setting: This pilot randomized open label trial was conducted in a single antenatal clinic in India.Subjects: One hundred women with singleton pregnancy and gestational diabetes diagnosed between 14-28 weeks' gestation were included. Overt diabetes, twin pregnancy, pre-existing renal disease, heart disease and other chronic medical disorders were exclusions.Intervention: Participants were randomized in two groups (1:1 ratio) by opaque envelope method. Individualized nutrition counseling with dietary modification and routine antenatal care was provided to all. Fifty women received myoinositol 1000 mg twice daily; 50 controls did not receive myoinositol. Fasting and postprandial glucose levels were assessed after two weeks. Women not achieving glycemic targets (fasting glucose <95 and postprandial glucose <120 mg/dL) were given pharmacologic therapy. Contributory factors in women requiring additional pharmacologic therapy, maternal and fetal outcomes were noted.Statistical Analysis: Between group comparisons reported relative risk and mean difference. To assess predictive factors for need for pharmacologic therapy, univariate and multivariable logistic regression analysis were used.Results: Baseline characteristics were comparable in both groups. Except one woman in the myoinositol group, all women provided glycaemia data throughout their pregnancy. Glycemic control was achieved in 44/ 49 (89.8 %) women in myoinositol group which was significantly higher than 34/50 (68 %) in the controls ((relative risk 0.31, 95 % confidence interval 0.13 to 0.80, p = 0.008). Mean duration of myoinositol treatment was 17.6 weeks (standard deviation 5.3). Additional treatment with metformin/insulin was needed in all women failing to achieve glycaemic control. The mean (range) dose of insulin was 25.3 units in myoinositol group compared to 14.27 units in controls (p = 0.058). Secondary outcomes were similar in two groups except baby weight which was higher in controls (p = 0.018).Conclusions: Oral supplementation with myoinositol in dose of 1 gm twice-daily, when started soon after the diagnosis of GDM, is effective in achieving glycemic control and decreasing the need for additional pharmacological therapy in Asian Indian women. [ABSTRACT FROM AUTHOR]

Objective: A randomized controlled trial was conducted to compare myoinositol with metiormin in treating polycystic ovary syndrome(PCOS) in terms of improvement in clinical, hormonal and metabolic parameters. Materials and Methods: Total 50 cases of PCOS were recruited and randomized into two groups. Group-1 (n=25) received oral myoinositol 1g twice daily and group-2 (n=25) received oral sustained-release metiormin 850 mg twice daily for six months. Outcome measures were clinical response and effect on ovarian (ultrasound), hormonal and metabolic parameters (glycemic, insulinemic and lipid profile). Adverse effects were noted. Patients were followed up three months after stopping the treatment to assess persistent effect of treatment. Results: Baseline profile of patients was comparable and clinical symptoms improved in both groups. Cyclicity improved betier with myoinositol. Regular cycles were seen in 68% vs. 28%, cycle length was 34 vs. 45 days and cycles per year were 9.4 vs. 8.4 (p=<0.05) with myoinositol and metiormin respectively. Reduction in hirsutism and acne was similar. Ovaries achieved betier morphology with myoinositol in terms of volume and stromal thickness on ultrasound. Significant reduction was seen in testosterone (20%, p=0.005) and LH/FSH ratio (12.3 % p=0.02) only with myoinositol. Among metabolic parameters, lipids (total cholesterol, HDL, LDL) and blood sugars improved betier with metiormin; whereas effect on insulinemic parameters (insulin, HOMA-IR) was similar. Lesser side effects were noted with myoinositol. Based on results, Nutan's proposed treatment preference for two insulin sensitizers i.e. myoinositol or metiormin, in PCOS (different clinical scenarios of PCOS) is suggested. Conclusion: Myoinositol is effective in treating PCOS and comparable to metiormin in improving insulin sensitivity. It ameliorates menstrual cyclicity, testosterone and ovarian morphology betier than metiormin whereas metiormin improves lipids and blood sugar betier than myoinositol. Selection of either or both of them can be done on basis of patient profile. As myoinositol is a natural nutraceutical with lesser side effects it can be a good option with betier patient compliance in treating PCOS. [ABSTRACT FROM AUTHOR]

To evaluate the benefits of myoinositol plus metformin versus myoinositol alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction cycles. Total 116 infertile PCOS women were randomized: Group I (n = 57): metformin (1500 mg) plus myoinositol (4 g) per day; Group II (n=59): myoinositol 4 g per day. Subjects were advised to try for spontaneous conception. Those who did not conceive after three months were given three cycles of ovulation induction. Primary outcome was clinical pregnancy rate after 6 months. Secondary outcomes were improvement in metabolic and endocrine parameters, ongoing pregnancy, abortion and multiple pregnancy rate. Baseline demographic, metabolic and hormonal parameters were comparable in two groups. After 3 months of therapy, both study groups had comparable improvement in metabolic and hormonal parameters. After 6 months, clinical pregnancy rate was 42.0% in Group I and 45.5% Group II respectively (RR 0.92(95% CI:0.60–1.43) (p >.05). Side-effects (mainly gastrointestinal) were significantly higher in Group I than group II. Myoinositol (4 g) might be used alone as an insulin sensitizer to improve metabolic, hormonal and reproductive outcome in infertile PCOS women. Further studies with large numbers are warranted to confirm the role of myoinostiol as a sole insulin sensitizer. [ABSTRACT FROM AUTHOR]

Context. Cardiovascular risk is increased in women with polycystic ovary syndrome (PCOS). Do insulin sensitizing agents such as metformin (MET) and myoinositol (MI) ameliorate biomarkers of cardiovascular risk? Objective. To compare the effects of MET and MI on blood pressure, lipid profile and high sensitive C-reactive protein (hs-CRP) in women with PCOS in respect to their body mass index (BMI). Design. Open label, parallel randomized, single center study. Subjects and Methods. Sixty six women with PCOS (33 normal-weight and 33 overweight/obese) were randomized to either MI (4 g/day) or MET (1500 mg/day) for a period of 6 months. Serum concentration of hormones, lipid profile, oxidized LDL (ox-LDL), hs-CRP, blood pressure measurement and clinical assessment of BMI, waist circumference (WC) and Ferriman Gallwey score (FG score) were performed before and after treatment. Results. Thirty patients in each group completed the trial. Compared with MET, MI significantly decreased diastolic blood pressure (DBP) (p=0.036) and significantly increased serum hs-CRP (p=0.043). No differences between groups in total cholesterol (TC), HDL-cholesterol, LDLcholesterol, ox-LDL and triglycerides were reported after 6 months. Treatment with MI reduced BMI (p=0.037), WC (p=0.005), DBP (p=0.021) and TC (p=0.008). During MET treatment a significant decrease in BMI (p=0.005), WC (p=0.004), FG score (p=0.001), testosterone (p=0.013) and free androgen index (FAI) (p=0.006) was observed. Conclusions. Our study showed an advantage of MI in reduction of DBP and TC thus predicting favorable metabolic and cardiovascular outcomes in PCOS women. MET more effectively decrease indices of hyperandrogenism. [ABSTRACT FROM AUTHOR]

Copyright of Ginecología y Obstetricia de México is the property of Federacion Mexicana de Ginecologia y Obstetricia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Omega-3 fatty acids sourced from microalgae are in demand due to their therapeutic potential and sustainability of the source. The present study was focused towards enhancing eicosapentaenoic acid (EPA) productivity in the marine Chrysophyte Monodopsis subterranea through media supplementation using the plant growth regulators gibberellic acid, methyl jasmonate and myoinositol. The effect of three concentrations (1 μM, 10 μM and 100 μM) of supplements on biomass yield, fatty acid composition, total fatty acid (TFA) and EPA productivity were analyzed at three phases of microalgal growth. Supplementation with 100 μM GA increased biomass yield and TFA productivity by 3.3-fold and 3.9-fold respectively at the mid-exponential phase and EPA productivity increased up to 3.2-fold at the late-exponential phase. The addition of 1 μM MeJA stimulated biomass accumulation to 2.7-fold at the late-stationary phase, but this effect was reduced to 1.1–1.4-fold at higher concentrations. The addition of 10 μM MI also showed a positive effect on TFA productivity and thus increased EPA productivity by 1.8-fold at the late-stationary phase. Supplementation with 100 μM GA, 100 μM MeJA and 10 μM MI at the late-stationary phase increased all fatty acids except 18:0 and 18:2. EPA was negatively correlated with 18:2 at all three growth phases. Principal components analysis indicated a strong relationship between key fatty acids and EPA at all three growth stages and associated with 100 μM GA. [ABSTRACT FROM AUTHOR]

Natural or synthetic compounds that interfere with the bioavailability of nutrients are called antinutrients. Phytic acid (PA) is one of the major antinutrients present in the grains and acts as a chelator of micronutrients. The presence of six reactive phosphate groups in PA hinders the absorption of micronutrients in the gut of non-ruminants. Consumption of PA-rich diet leads to deficiency of minerals such as iron and zinc among human population. On the contrary, PA is a natural antioxidant, and PA-derived molecules function in various signal transduction pathways. Therefore, optimal concentration of PA needs to be maintained in plants to avoid adverse pleiotropic effects, as well as to ensure micronutrient bioavailability in the diets. Given this, the chapter enumerates the structure, biosynthesis, and accumulation of PA in food grains followed by their roles in growth, development, and stress responses. Further, the chapter elaborates on the antinutritional properties of PA and explains the conventional breeding and transgene-based approaches deployed to develop low-PA varieties. Studies have shown that conventional breeding methods could develop low-PA lines; however, the pleiotropic effects of these methods viz. reduced yield, embryo abnormalities, and poor seed quality hinder the use of breeding strategies. Overexpression of phytase in the endosperm and RNAi-mediated silencing of genes involved in myo-inositol biosynthesis overcome these constraints. Next-generation genome editing approaches, including CRISPR-Cas9 enable the manipulation of more than one gene involved in PA biosynthesis pathway through multiplex editing, and scope exists to deploy such tools in developing varieties with optimal PA levels. [ABSTRACT FROM AUTHOR]